November 14, 2025

How the biological clock ticks in the female reproductive tract – Breakthrough of the Year Award 2025 for Ângela Gonçalves

How the biological clock ticks in the female reproductive tract – Breakthrough of the Year Award 2025 for Ângela Gonçalves

Endometriosis, menopause, ovarian cancer – still poorly researched and often misdiagnosed. Ângela Gonçalves combines AI, molecular biology, and clinical findings to develop non-invasive tools for early detection, personalized care, and healthier aging – directly challenging gender bias in medicine. The scientist from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim is the winner of the Falling Walls Foundation’s “Breakthrough of the Year 2025” award in the Women’s Impact category.

(C) Jung/DKFZ

Each menstrual cycle, the organs of female reproductive tract organs undergo tremendous buildup and remodeling followed by breakdown and repair. For a long time, it was assumed that these events left no traces or scars in the affected organs. Ângela Gonçalves’ research has revealed the unexpected price of female reproductive capacity that results from the constant remodeling of the female reproductive tract. She has also been exploring pioneering solutions for non-invasive diagnosis by using menstrual blood. For this, the Falling Walls Foundation is honoring her with the Breakthrough of the Year award in the Women’s Impact category.

Ângela Gonçalves studied computer science at the University of Coimbra in Portugal. After a research stay at the European Space Agency, she received a scholarship for a PhD in computational molecular biology at the European Bioinformatics Institute (EMBL EBI) and received her PhD from the University of Cambridge in 2012. She then conducted postdoctoral research in population genomics at the Wellcome Trust Sanger Institute.

Since 2018, Gonçalves has headed the Division of Computational and Molecular Prevention at the German Cancer Research Center (DKFZ). Since 2022, she has also been co-head of the Digital Cancer Prevention group at the National Cancer Prevention Center, and since 2024, she has been a full professor at Heidelberg University.

In 2025, the Hector Foundation II generously increased its funding for the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim. This enabled the establishment of research areas such as prevention, early detection, and survivorship. As part of this expansion, Gonçalves was appointed to the DKFZ-Hector Cancer Institute. There, she investigates how mutated cell clones arise and spread before malignant tumors develop. To study these early stages, she combines experimental approaches with bioinformatic analyses and statistical modeling—with the long-term goal of improving cancer prevention.

The DKFZ-Hector Cancer Institute at the University Medical Center Mannheim is a collaboration between the German Cancer Research Center (DKFZ), the Mannheim Medical Faculty, Heidelberg University, and the Mannheim University Hospital.

Falling Walls Science Summit 2025

The Falling Walls Science Breakthrough of the Year awards are presented annually. They recognize the most significant scientific breakthroughs in various categories of the Falling Walls Global Call. The award winners will present their work to the public on November 9, 2025, at the Falling Walls Science Summit in Berlin.

Our latest News

discover more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

New AI System Provides Treatment Recommendations for Complex Blood Cancers

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp